Post-traumatic Stress Disorder (PTSD) Clinical Trial
Official title:
Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Metabolism and Function in Post-traumatic Stress Disorder (PTSD)
Verified date | June 2021 |
Source | The University of Texas at Arlington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effects of transcranial infrared laser stimulation (TILS) on prefrontal metabolism and hemodynamics in veterans with post-traumatic stress disorder (PTSD). The subjects will receive six TILS interventions and one sham intervention in a course of seven weeks.
Status | Terminated |
Enrollment | 10 |
Est. completion date | October 8, 2019 |
Est. primary completion date | October 8, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - War-zone and non-war-zone veterans - Ages 18-60 years old - Males and females - Able to read, speak, and understand English - Medical records showing prior diagnosis of PTSD (here it refers to the records prior to TILS, which will be assessed and obtained in Visit 1) - Medical records showing diagnosis of PTSD (here it refers to the CAPS-5 record prior to TILS, which will be assessed and obtained in Visit 1) - On stable doses of any psychotropic medications for at least 4 weeks Exclusion Criteria: - Significant physical disability to perform a computerized memory task - Past/current significant medical/neurological/mental health disorders known to affect cognitive functioning (e.g., stroke, dementia, schizophrenia, AIDS) - Presence of moderate/severe TBI, defined as having: alteration of consciousness/mental state >24 hours; posttraumatic amnesia >1 day; loss of consciousness >30 minutes; and/or abnormal structural neuroimaging. We will not exclude veterans with mild TBI, which is found in nearly 50% of veterans with PTSD - Alcohol abuse/dependence for the past 12- months, as determined by the Rapid Alcohol Problems Screen score >0 - Drug abuse/dependence for the past 12- months, as determined by the Drug Abuse Screening Test-10 score >2 - Severe depression (PHQ-9 total score >19), significant risk of suicide (SBQ-R >6), severe headache (PHQ-15, Item e =2), and/or severe dizziness (PHQ-15, Item g =2) - Opiate use in the month prior to study entry |
Country | Name | City | State |
---|---|---|---|
United States | Engineering Research Building (ERB), University of Texas Arlington | Arlington | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas at Arlington | University of Texas at Austin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cerebral CCO Changes in Response to TILS and Sham | Cerebral CCO changes measured by broadband NIRS during six TILS interventions and one sham session. | 7 weeks | |
Primary | Cerebral Hemodynamic Changes in Response to TILS and Sham | Cerebral hemodynamic changes measured by broadband NIRS during every TILS or sham session | 7 weeks | |
Secondary | Short-term Memory Scores | The participant's recall time in Digit Forward (DF) task and Digit Backward (DB) task was recorded recorded during initial baseline, and after the one sham and six TILS sessions.
The recall time indicates how fast the participants could recall that digital numbers 10 seconds after they vanished on computer screen. |
8 weeks | |
Secondary | Prefrontal Activations in Short-term Memory Processing | Anterior prefrontal hemodynamic activations (HbO2 and Hb changes) measured by functional NIRS during the Digit Forward (DF) and Digit Backward (DB) tasks. The activations were recorded from initial baseline, and after the one sham and six TILS sessions. In post-experiment processing, the activations were averaged in the recall phase, which was a key component related to PTSD. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05189977 -
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
|
Phase 1 | |
Completed |
NCT01806168 -
rTMS in the Treatment of PTSD
|
N/A | |
Not yet recruiting |
NCT06194851 -
Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD
|
Phase 2 | |
Completed |
NCT02187224 -
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
|
Phase 2/Phase 3 | |
Completed |
NCT02549508 -
Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD
|
N/A | |
Completed |
NCT02012738 -
Treatment of Trauma and Violence in the Townships of South Africa
|
N/A | |
Not yet recruiting |
NCT01940549 -
Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder
|
N/A | |
Not yet recruiting |
NCT06419959 -
NightWare and Cardiovascular Health in Veterans With PTSD
|
N/A | |
Completed |
NCT04891614 -
The PRISM Pilot Trial for Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT05407337 -
The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme
|
N/A | |
Completed |
NCT02030522 -
Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma
|
N/A | |
Completed |
NCT01729325 -
Prevention of Post-Traumatic Stress Disorder in Soldiers
|
Phase 2 | |
Completed |
NCT02053532 -
Functional Brain Imaging in PTSD
|
N/A | |
Not yet recruiting |
NCT02598024 -
Treating Earthquake in Nepal Trauma (TENT) Trial 2016
|
N/A | |
Terminated |
NCT02237703 -
Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)
|
N/A | |
Withdrawn |
NCT02356861 -
LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans
|
N/A | |
Not yet recruiting |
NCT05974631 -
Evaluating Treatments for Suicidal Veterans With PTSD
|
N/A | |
Not yet recruiting |
NCT06288594 -
TraumaRelief App: A Pilot RCT Assessing Feasibility and Acceptability
|
N/A | |
Completed |
NCT01847469 -
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
|
Phase 2 | |
Completed |
NCT01691092 -
PET Imaging of mGLuR5 With Drug Challenge
|
N/A |